Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.Hata A, Ninomaru T, Okada H, et al. Lancet Oncol. 2025 Oct 10:S1470-2045(25)00462…